Lp-PLA2 is an enzyme that circulates in the blood and attaches to cholesterol in the blood stream. It is an important marker of inflammation, just like C reactive protein.
Here's more information on Lp-PLA2
Lp-PLA2 is also an important marker in endothelial dysfunction.
What the Buffalo researchers found is that this enzyme shows up in the blood of pwMS---and levels are significantly higher than in controls.
Lp-PLA2: Inflammatory Biomarker of Vascular Risk in Multiple Sclerosis.
A member of the A2 phospholipase superfamily, the enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2), is involved in atherogenic processes. Lp-PLA2 mass and activity were measured by the enzyme-linked immunosorbent assay and by a colorimetric method, respectively, and compared among 63 multiple sclerosis (MS) patients and 47 age-matched healthy controls (HCs). Lp-PLA2 plasma levels were significantly higher in MS patients (236.7 ± 10 ng/ml) compared to HCs (197.0 ± 7 ng/ml) (p = 0.003)
Here is a study of plasma levels of Lp-PLA2 in those with coronary disease and normals. Lp-PLA2 is a marker of endothelial dysfunction. ( Note that pwMS had a 236.7 ng/ml level, and those with coronary arterial disease had a 246.2 ng/ml level. Normals have around a 200 ng/ml level.)
Patients (172) with no significant coronary artery disease ( Patients with coronary endothelial dysfunction had significantly higher serum concentrations of Lp-PLA2 than those with normal endothelial function (246.2+/-71.6 versus 209+/-56.7 ng/mL; P=0.001). The odds ratio for coronary endothelial dysfunction in patients with Lp-PLA2 in the highest tertile was 3.3 (95% CI, 1.6 to 6.6).
Lp-PLA2 is independently associated with coronary artery endothelial dysfunction and is a strong predictor of endothelial dysfunction in humans.